CureVac N.V.'s latest marketcap:
As of 07/05/2025, CureVac N.V.'s market capitalization has reached $1.23 B. According to our data, CureVac N.V. is the 8514th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 1.23 B |
| Revenue (ttm) | 566.04 M |
| Net Income (ttm) | 195.26 M |
| Shares Out | 225.17 M |
| EPS (ttm) | 0.87 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/14/2025 |
CureVac N.V.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $1.23 B | 60.44% | 8514 |
| 12/31/2024 | $764.91 M | -18.86% | 10271 |
| 12/29/2023 | $942.72 M | -17.82% | 9005 |
| 12/30/2022 | $1.15 B | -82.12% | 7611 |
| 12/31/2021 | $6.42 B | -55.14% | 2618 |
| 12/31/2020 | $14.31 B | 1177 |
Company Profile
About CureVac N.V.
CureVac N.V. is a pioneering biopharmaceutical company specializing in transformative medicines based on messenger ribonucleic acid (mRNA) technology. Headquartered in Tübingen, Germany, and founded in 2000, the company leverages its expertise to develop innovative therapies across multiple disease areas.
Core Focus Areas
- Prophylactic Vaccines: Targeting infectious diseases, including urinary tract infections (UPEC bacteria) and SARS-CoV-2 variants.
- Oncology: Developing off-the-shelf and personalized cancer immunotherapies.
- Molecular Therapy: Optimizing mRNA to stimulate therapeutic protein production in human cells.
Key Technologies & Products
- The RNA Printer: A fully automated, compact system for mRNA vaccine and therapeutic manufacturing.
- Clinical Candidates: Includes CV0601 and CV0701 (Phase 2 for SARS-CoV-2), CVGBM (for glioblastoma), and precision immunotherapies for non-small cell lung cancer.
- mRNA Delivery: Enables targeted protein production in cells, enhancing therapeutic efficacy.
CureVac continues to advance its pipeline, focusing on cutting-edge mRNA solutions to address unmet medical needs in vaccines, oncology, and beyond.
Frequently Asked Questions
-
What is CureVac N.V.'s (CVAC) current market cap?As of 07/05/2025, CureVac N.V. (including the parent company, if applicable) has an estimated market capitalization of $1.23 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does CureVac N.V. (CVAC) rank globally by market cap?CureVac N.V. global market capitalization ranking is approximately 8514 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.